Gerard Sanacora - Publications

Affiliations: 
Yale University, New Haven, CT 
Area:
Psychiatry

114 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, ... Sanacora G, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry. PMID 35165397 DOI: 10.1038/s41380-022-01465-2  0.458
2022 Averill LA, Averill CL, Gueorguieva R, Fouda S, Sherif M, Ahn KH, Ranganathan M, D'Souza DC, Southwick SM, Sanacora G, Duman RS, Krystal JH, Abdallah CG. mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal of Affective Disorders. PMID 35101523 DOI: 10.1016/j.jad.2022.01.104  0.456
2021 McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. The American Journal of Psychiatry. appiajp202020081251. PMID 33726522 DOI: 10.1176/appi.ajp.2020.20081251  0.329
2020 Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, et al. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32544925 DOI: 10.1038/S41386-020-0738-4  0.302
2020 Pothula S, Kato T, Liu RJ, Wu M, Gerhard D, Shinohara R, Sliby AN, Chowdhury GMI, Behar KL, Sanacora G, Banerjee P, Duman RS. Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry. PMID 32488125 DOI: 10.1038/s41380-020-0796-3  0.325
2020 Averill LA, Abdallah CG, Fenton LR, Fasula MK, Jiang L, Rothman DL, Mason GF, Sanacora G. Early life stress and glutamate neurotransmission in major depressive disorder. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 32418842 DOI: 10.1016/j.euroneuro.2020.03.015  0.362
2020 Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). The Journal of Clinical Psychiatry. 81. PMID 32412700 DOI: 10.4088/JCP.19m13191  0.418
2020 Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology. 40: 287-292. PMID 32332464 DOI: 10.1097/Jcp.0000000000001209  0.41
2020 Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, et al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). The Journal of Clinical Psychiatry. 81. PMID 32316080 DOI: 10.4088/JCP.19m12891  0.371
2020 Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, et al. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nature Medicine. PMID 32231295 DOI: 10.1038/S41591-020-0806-7  0.326
2020 Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D'Souza DC, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32092760 DOI: 10.1038/S41386-020-0644-9  0.558
2020 Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, Caliman-Fontes AT, Marques BLS, Bezerra MLO, Dias-Neto AL, Silva SS, ... ... Sanacora G, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. European Archives of Psychiatry and Clinical Neuroscience. PMID 32078034 DOI: 10.1007/S00406-020-01110-5  0.403
2019 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 31734084 DOI: 10.1016/j.jagp.2019.10.008  0.401
2019 Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders. 260: 131-139. PMID 31494365 DOI: 10.1016/J.Jad.2019.09.017  0.4
2019 Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Lower synaptic density is associated with depression severity and network alterations. Nature Communications. 10: 1529. PMID 30948709 DOI: 10.1038/S41467-019-09562-7  0.519
2019 Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 102: 75-90. PMID 30946828 DOI: 10.1016/J.Neuron.2019.03.013  0.434
2019 Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 101: 774-778. PMID 30844397 DOI: 10.1016/J.Neuron.2019.02.005  0.641
2019 Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research. 110: 166-171. PMID 30641350 DOI: 10.1016/J.Jpsychires.2019.01.010  0.356
2019 Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, ... Sanacora G, et al. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry. PMID 30617276 DOI: 10.1038/S41380-018-0311-2  0.349
2019 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets WC, Sanacora G, Adler C, McShane R, Gaillard R, Singh JB. POST HOC ANALYSES OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION The American Journal of Geriatric Psychiatry. 27: S181-S182. DOI: 10.1016/J.JAGP.2019.01.094  0.388
2019 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets WC, Sanacora G, Adler C, McShane R, Gaillard R, Singh JB. EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSION The American Journal of Geriatric Psychiatry. 27: S180-S181. DOI: 10.1016/J.Jagp.2019.01.093  0.346
2019 Wajs E, Leah A, Morrison R, Daly E, Lane R, Lim P, Holder R, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, et al. Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study European Neuropsychopharmacology. 29. DOI: 10.1016/J.Euroneuro.2018.11.1016  0.369
2019 Holmes S, Scheinost D, Finnema S, Naganawa M, Davis M, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Pietrzak R, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. 142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations Biological Psychiatry. 85. DOI: 10.1016/J.Biopsych.2019.03.156  0.495
2018 Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression and Anxiety. PMID 30597688 DOI: 10.1002/Da.22875  0.417
2018 Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, et al. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials. PMID 30572160 DOI: 10.1016/J.Cct.2018.12.009  0.418
2018 Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, ... Sanacora G, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry. PMID 30283029 DOI: 10.1038/S41380-018-0256-5  0.333
2018 Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 29977074 DOI: 10.1038/S41386-018-0136-3  0.505
2018 Abdallah CG, Sanacora G, Duman RS, Krystal JH. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacology & Therapeutics. PMID 29803629 DOI: 10.1016/J.Pharmthera.2018.05.010  0.434
2018 Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. The American Journal of Psychiatry. appiajp201817060720. PMID 29656663 DOI: 10.1176/Appi.Ajp.2018.17060720  0.361
2018 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Foster K, Hough D, Manji H, Drevets WC, Sanacora G, Adler C, McShane R, Gaillard R, Singh JB. S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.1005  0.382
2017 van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. Journal of Affective Disorders. 227: 11-16. PMID 29045915 DOI: 10.1016/J.Jad.2017.09.023  0.315
2017 Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, et al. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimulation. PMID 29030111 DOI: 10.1016/J.Brs.2017.09.010  0.387
2017 Abdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N, Sanacora G, Jiang L, Matuskey D, Satodiya R, Gasparini F, Lin X, Javitch J, Planeta B, Nabulsi N, Carson RE, et al. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 2: 449-456. PMID 28993818 DOI: 10.1016/J.Bpsc.2017.03.019  0.401
2017 Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports. 19: 74. PMID 28844076 DOI: 10.1007/S11920-017-0829-Z  0.451
2017 Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28553836 DOI: 10.1038/npp.2017.106  0.431
2017 Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [(11)C]ABP688 and PET imaging study in depression. Molecular Psychiatry. PMID 28397841 DOI: 10.1038/Mp.2017.58  0.682
2016 Sanacora G, Johnson M, Khan A, Atkinson S, Riesenberg R, Schronen J, Burke MA, Zajecka J, Barra L, Su HL, Posener JA, Bui K, Quirk M, Piser T, Mathew SJ, et al. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27681442 DOI: 10.1038/Npp.2016.224  0.425
2016 Haroon E, Miller AH, Sanacora G. Inflammation, Glutamate and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27629368 DOI: 10.1038/npp.2016.199  0.323
2016 Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AF, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, ... ... Sanacora G, et al. Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry. 80: 84-6. PMID 27346079 DOI: 10.1016/J.Biopsych.2016.05.004  0.387
2016 Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B, Bristow L, Schaeffer E, Duman RS, Rothman DL, Behar KL, Sanacora G. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Molecular Psychiatry. PMID 27067013 DOI: 10.1038/mp.2016.34  0.346
2016 Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. Depression and Anxiety. PMID 27062302 DOI: 10.1002/Da.22501  0.515
2016 Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. The American Journal of Psychiatry. appiajp201616010037. PMID 27056608 DOI: 10.1176/Appi.Ajp.2016.16010037  0.427
2016 Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine. 22: 238-49. PMID 26937618 DOI: 10.1038/Nm.4050  0.434
2016 Krystal JH, Sanacora G, Abdallah C, Duman R. Speaker 4: John Krystal, USA. The International Journal of Neuropsychopharmacology. 19: 19-19. DOI: 10.1093/Ijnp/Pyw042.052  0.434
2015 Niciu MJ, Abdallah CG, Fenton LR, Fasula MK, Black A, Anderson GM, Sanacora G. A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder. Journal of Affective Disorders. 187: 241-4. PMID 26363143 DOI: 10.1016/J.Jad.2015.08.026  0.369
2015 Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. The Journal of Clinical Psychiatry. 76: 1075-84. PMID 26214725 DOI: 10.4088/Jcp.14M09123  0.612
2015 da Frota Ribeiro CM, Sanacora G, Hoffman R, Ostroff R. The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms: To the Editor. Biological Psychiatry. PMID 26212896 DOI: 10.1016/J.Biopsych.2015.05.016  0.397
2015 McCullumsmith RE, Sanacora G. Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 254-5. PMID 25482181 DOI: 10.1038/Npp.2014.218  0.326
2015 Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annual Review of Medicine. 66: 509-23. PMID 25341010 DOI: 10.1146/Annurev-Med-053013-062946  0.57
2015 DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Yang J, Wen R, Mann JJ, Krystal JH, Parsey RV, Carson RE, Esterlis I. In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biological Psychiatry. 77: 266-75. PMID 25156701 DOI: 10.1016/J.Biopsych.2014.06.024  0.365
2014 Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, Mason GF, Sanacora G. Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychotherapy and Psychosomatics. 83: 298-307. PMID 25116726 DOI: 10.1159/000361078  0.407
2014 Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL, Mason GF, Sanacora G. Glutamate metabolism in major depressive disorder. The American Journal of Psychiatry. 171: 1320-7. PMID 25073688 DOI: 10.1176/Appi.Ajp.2014.14010067  0.536
2014 Singh J, Fedgchin M, Daly E, Boer PD, Cooper K, Lim P, Pinter C, Murrough J, Sanacora G, Shelton R, Kurian B, Winokur A, Fava M, Manji H, Drevets W, et al. P.2.b.017 Onset of efficacy of ketamine in treatment-resistant depression: a double-blind, randomised, placebo-controlled, dose frequency study European Neuropsychopharmacology. 24. DOI: 10.1016/S0924-977X(14)70618-2  0.372
2013 Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biological Psychiatry. 74: 742-9. PMID 23751205 DOI: 10.1016/J.Biopsych.2013.04.025  0.34
2013 Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biological Psychiatry. 73: 1133-41. PMID 23726151 DOI: 10.1016/J.Biopsych.2013.03.026  0.434
2013 Cardoos A, Inamori A, Sanacora G, Fava M, Mischoulon D. Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. Psychosomatics. 54: 488-92. PMID 23473447 DOI: 10.1016/j.psym.2013.02.002  0.418
2012 Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. The Journal of Ect. 28: 157-61. PMID 22847373 DOI: 10.1097/YCT.0b013e31824f8296  0.44
2012 Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biological Psychiatry. 72: 964-70. PMID 22784486 DOI: 10.1016/J.Biopsych.2012.05.028  0.621
2012 Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biological Psychiatry. 72: e27-8. PMID 22771240 DOI: 10.1016/J.Biopsych.2012.05.031  0.378
2012 McCarthy DJ, Alexander R, Smith MA, Pathak S, Kanes S, Lee CM, Sanacora G. Glutamate-based depression GBD. Medical Hypotheses. 78: 675-81. PMID 22391030 DOI: 10.1016/j.mehy.2012.02.009  0.435
2012 Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biological Psychiatry. 71: 1022-5. PMID 22169441 DOI: 10.1016/j.biopsych.2011.11.006  0.312
2012 Gomez R, Behar KL, Watzl J, Weinzimer SA, Gulanski B, Sanacora G, Koretski J, Guidone E, Jiang L, Petrakis IL, Pittman B, Krystal JH, Mason GF. Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla. Biological Psychiatry. 71: 239-46. PMID 21855054 DOI: 10.1016/J.Biopsych.2011.06.026  0.454
2012 Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 62: 63-77. PMID 21827775 DOI: 10.1016/J.Neuropharm.2011.07.036  0.447
2012 Gourley SL, Espitia JW, Sanacora G, Taylor JR. Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology. 219: 805-14. PMID 21779782 DOI: 10.1007/s00213-011-2403-4  0.348
2011 Kelmendi B, Holsbach-Beltrame M, McIntosh AM, Hilt L, George ED, Kitchen RR, Carlyle BC, Pittenger C, Coric V, Nolen-Hoeksema S, Sanacora G, Simen AA. Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neuroscience Letters. 496: 195-9. PMID 21529705 DOI: 10.1016/J.Neulet.2011.04.026  0.579
2011 Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Research. 191: 122-7. PMID 21232924 DOI: 10.1016/J.Pscychresns.2010.10.009  0.547
2011 Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry. 72: 744-50. PMID 21034692 DOI: 10.4088/JCP.09m05659gre  0.431
2011 Larkin G, Beautrais A, Turelli R, Sanacora G, Powsner S, Lippmann M, Krystal J. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department European Psychiatry. 26: 1607-1607. DOI: 10.1016/S0924-9338(11)73311-9  0.354
2010 Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G, Rajkowska G. Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biological Psychiatry. 67: 465-70. PMID 20004363 DOI: 10.1016/J.Biopsych.2009.10.027  0.418
2010 Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry. 15: 501-11. PMID 18825147 DOI: 10.1038/mp.2008.106  0.382
2010 Sanacora G, Banasr M, Chowdhury G, Lepak A, Behar K. S.28.05 Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioural deficits by the glutamate-modulating drug riluzole European Neuropsychopharmacology. 20. DOI: 10.1016/S0924-977X(10)70241-8  0.349
2010 Larkin G, Beautrais A, Powsner S, Sanacora G, Krystal J, Turelli R, Lippmann M. 157: A Prospective Open Label Trial of Low Dose Ketamine for Acute Suicidal States In the Emergency Department Annals of Emergency Medicine. 56: S53. DOI: 10.1016/J.ANNEMERGMED.2010.06.204  0.354
2010 Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target of the pharmacotherapy of anxiety disorders, mood disorders and schizophrenia | Neuroplastyczność jako cel dla farmakoterapii zaburzeń lȩkowych, zaburzeń nastroju i schizofrenii Wiadomosci Psychiatryczne. 13: 163-173.  0.354
2009 Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today. 14: 690-7. PMID 19460458 DOI: 10.1016/J.Drudis.2009.05.002  0.489
2009 Valentine GW, Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochemical Pharmacology. 78: 431-9. PMID 19376090 DOI: 10.1016/j.bcp.2009.04.008  0.384
2008 Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. Cns Drugs. 22: 761-86. PMID 18698875 DOI: 10.2165/00023210-200822090-00004  0.686
2008 Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews. Drug Discovery. 7: 426-37. PMID 18425072 DOI: 10.1038/Nrd2462  0.489
2008 Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, ... ... Sanacora G, et al. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biological Psychiatry. 63: 725-7. PMID 18371494 DOI: 10.1016/J.Biopsych.2008.03.005  0.502
2007 Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. Cns & Neurological Disorders Drug Targets. 6: 101-15. PMID 17430148 DOI: 10.2174/187152707780363267  0.621
2007 Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry. 61: 822-5. PMID 17141740 DOI: 10.1016/J.Biopsych.2006.08.037  0.58
2007 Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biological Psychiatry. 61: 250-2. PMID 16860779 DOI: 10.1016/j.biopsych.2006.04.037  0.671
2006 Pittenger C, Naungayan C, Kendell SF, Coric V, Malison R, Krystal JH, Sanacora GS. Visual hallucinations from the addition of riluzole to memantine and bupropion. Journal of Clinical Psychopharmacology. 26: 218-20. PMID 16633160 DOI: 10.1097/01.Jcp.0000203228.64117.9F  0.553
2006 Geracioti TD, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. The American Journal of Psychiatry. 163: 637-43. PMID 16585438 DOI: 10.1176/Ajp.2006.163.4.637  0.348
2006 Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology. 184: 254-6. PMID 16374600 DOI: 10.1007/S00213-005-0246-6  0.668
2006 Staley JK, Sanacora G, Tamagnan G, Maciejewski PK, Malison RT, Berman RM, Vythilingam M, Kugaya A, Baldwin RM, Seibyl JP, Charney D, Innis RB. Sex differences in diencephalon serotonin transporter availability in major depression. Biological Psychiatry. 59: 40-7. PMID 16139815 DOI: 10.1016/J.Biopsych.2005.06.012  0.528
2006 Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GF. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biological Psychiatry. 59: 284-6. PMID 16139814 DOI: 10.1016/J.Biopsych.2005.07.015  0.548
2005 Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. The American Journal of Psychiatry. 162: 1385-6. PMID 15994728 DOI: 10.1176/appi.ajp.162.7.1385  0.368
2005 Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biological Psychiatry. 58: 424-8. PMID 15993857 DOI: 10.1016/J.Biopsych.2005.04.043  0.678
2005 Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion On Therapeutic Targets. 9: 153-68. PMID 15757488 DOI: 10.1517/14728222.9.1.153  0.354
2005 Epperson CN, O'Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G, Rothman DL, Krystal JH, Mason GF. Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biological Psychiatry. 57: 44-8. PMID 15607299 DOI: 10.1016/J.Biopsych.2004.09.021  0.458
2004 Sanacora G, Kendell SF, Fenton L, Coric V, Krystal JH. Riluzole augmentation for treatment-resistant depression. The American Journal of Psychiatry. 161: 2132. PMID 15514421 DOI: 10.1176/Appi.Ajp.161.11.2132  0.532
2004 Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry. 56: 497-502. PMID 15450785 DOI: 10.1016/J.Biopsych.2004.07.001  0.519
2004 Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry. 61: 705-13. PMID 15237082 DOI: 10.1001/Archpsyc.61.7.705  0.537
2004 Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS. Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 1166-71. PMID 15010697 DOI: 10.1038/Sj.Npp.1300418  0.478
2004 Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. The Journal of Clinical Psychiatry. 65: 238-43. PMID 15003079 DOI: 10.4088/Jcp.V65N0215  0.546
2004 Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, Price LH, Krystal J, Gelernter J. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 124: 81-6. PMID 14681921 DOI: 10.1002/Ajmg.B.20055  0.506
2003 Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. Annals of the New York Academy of Sciences. 1003: 292-308. PMID 14684453 DOI: 10.1196/Annals.1300.018  0.491
2003 Kugaya A, Sanacora G, Verhoeff NP, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB. Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biological Psychiatry. 54: 792-9. PMID 14550678 DOI: 10.1016/S0006-3223(02)01788-2  0.525
2003 Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. Increased cortical GABA concentrations in depressed patients receiving ECT. The American Journal of Psychiatry. 160: 577-9. PMID 12611844 DOI: 10.1176/Appi.Ajp.160.3.577  0.538
2002 Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry. 7: S71-80. PMID 11986998 DOI: 10.1038/Sj.Mp.4001021  0.622
2002 Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. The American Journal of Psychiatry. 159: 663-5. PMID 11925309 DOI: 10.1176/Appi.Ajp.159.4.663  0.539
2002 Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO, Wachen RM, Oren DA, Heninger GR, Charney DS. Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry. 51: 469-73. PMID 11922881 DOI: 10.1016/S0006-3223(01)01285-9  0.545
2001 Krystal JH, D'Souza DC, Sanacora G, Goddard AW, Charney DS. Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. The Medical Clinics of North America. 85: 559-77. PMID 11349473 DOI: 10.1016/S0025-7125(05)70329-1  0.601
2000 Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Critical Reviews in Neurobiology. 14: 23-45. PMID 11253954 DOI: 10.1615/Critrevneurobiol.V14.I1.20  0.564
2000 Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry. 47: 332-7. PMID 10686268 DOI: 10.1016/S0006-3223(99)00243-7  0.545
2000 Sanacora G, Mason G, Rothman D, Epperson C, Goddard A, Krystal J. 305. Reduced cortical GABA in depression is not due to decreased gray matter Biological Psychiatry. 47: S92. DOI: 10.1016/S0006-3223(00)00569-2  0.533
2000 Mason G, Sanacora G, Anand A, Epperson C, Goddard A, Rothman D, Charney D, Krystal J. 304. Cortical GABA reduced in unipolar but not bipolar depression Biological Psychiatry. 47: S92. DOI: 10.1016/S0006-3223(00)00568-0  0.546
2000 Berman R, Sanacora G, Narasimhan M, Oren D, Cappiello A, Charney D. 268. Simultaneous catecholamine and indoleamine depletion in unmedicated depressed subjects Biological Psychiatry. 47: S81. DOI: 10.1016/S0006-3223(00)00532-1  0.458
1999 Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Archives of General Psychiatry. 56: 1043-7. PMID 10565505 DOI: 10.1001/Archpsyc.56.11.1043  0.611
1999 Sanacora G, Rothman D, Krystal JH. Applications of magnetic resonance spectroscopy to psychiatry Neuroscientist. 5: 192-196. DOI: 10.1177/107385849900500316  0.425
1999 Sanacora G, Mason GF, Rothman DL, Berman RM, Charney DS, Ciarcia JJ, Krystal JH. 1. ECT Effects on Cortical GABA Levels as Determined by 1H-MRS The Journal of Ect. 15: 102. DOI: 10.1097/00124509-199903000-00009  0.547
1998 Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biological Psychiatry. 44: 1090-8. PMID 9836013 DOI: 10.1016/S0006-3223(98)00272-8  0.515
1998 Berman R, Boutros N, Narasimhan M, Sanacora G, Charney D. 322. Transcranial magnetic stimulation in treatment-refractory depression Biological Psychiatry. 43: S97. DOI: 10.1016/S0006-3223(98)90770-3  0.445
1998 Sanacora G, Goddard A, Gil R, D'Souza D, Abi-Saab W, Petroff O, Mattson R, Mason G, Behar K, Ciarcia J, Berman R, Charney D, Rothman D, Krystal J. 24. Quantification of cortical GABA levels in neuropsychiatric patients Biological Psychiatry. 43: S8. DOI: 10.1016/S0006-3223(98)90472-3  0.376
Show low-probability matches.